Table 1.
Cox regression analysis for the association between clinical characteristics and progression to critical illness within 28 days of follow-up.
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
|
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
|
| Age | 1.06 (1.04-1.08) | <0.001 | 1.05 (1.02-1.08) | <0.001 |
|
Period of hospital admission | ||||
| March 12-27 | 1.00 | 1.00 | ||
| March 28-April 11 | 0.25 (0.11-0.57) | 0.001 | 0.38 (0.15-0.94) | 0.04 |
| April 12-26 | 0.30 (0.13-0.67) | 0.004 | 0.68 (0.27-1.75) | 0.43 |
| April 27-May 12 | 0.07 (0.02-0.33) | 0.001 | 0.14 (0.03-0.72) | 0.02 |
| Lymphocyte <800/ mm3 | 4.53 (2.52-8.12) | <0.001 | 1.93 (1.00-3.75) | 0.05 |
| CRP ≥30 mg/dL | 12.80 (4.58-35.73) | <0.001 | 3.07 (1.00-9.44) | 0.05 |
| Procalcitonin ≥0.25 µg/L | 8.82 (4.90-15.86) | <0.001 | 2.12 (1.07-4.21) | 0.03 |
| D-dimer ≥1.0 mg/L | 6.02 (3.18-11.39) | <0.001 | - | |
| LDH ≥350 U/L | 4.26 (2.37-7.65) | <0.001 | 2.04 (1.06-3.94) | 0.03 |
| Number of co-morbidities | 1.79 (1.46-2.20) | <0.001 | 1.33 (1.05-1.68) | 0.02 |
|
WHO scale on admission | ||||
| 2&3 | 1.00 | 1.00 | ||
| 4&5 | 13.32 (6.41-27.66) | <0.001 | 4.15 (1.87-9.22) | <0.001 |
HR: Hazard ratios, CI: Confidence interval, CRP: C-reactive protein, LDH: Lactate dehydrogenase, WHO: World Health Organization.